124 related articles for article (PubMed ID: 20943808)
21. Nitric oxide and cyclic GMP functions in bone.
Kalyanaraman H; Schall N; Pilz RB
Nitric Oxide; 2018 Jun; 76():62-70. PubMed ID: 29550520
[TBL] [Abstract][Full Text] [Related]
22. Nitric oxide-cyclic GMP signaling in stem cell differentiation.
Mujoo K; Krumenacker JS; Murad F
Free Radic Biol Med; 2011 Dec; 51(12):2150-7. PubMed ID: 22019632
[TBL] [Abstract][Full Text] [Related]
23. Estrogen-induced apoptosis of breast epithelial cells is blocked by NO/cGMP and mediated by extranuclear estrogen receptors.
Kastrati I; Edirisinghe PD; Wijewickrama GT; Thatcher GR
Endocrinology; 2010 Dec; 151(12):5602-16. PubMed ID: 20943808
[TBL] [Abstract][Full Text] [Related]
24. Pro-survival effects of 17β-estradiol on osteocytes are mediated by nitric oxide/cGMP via differential actions of cGMP-dependent protein kinases I and II.
Marathe N; Rangaswami H; Zhuang S; Boss GR; Pilz RB
J Biol Chem; 2012 Jan; 287(2):978-88. PubMed ID: 22117068
[TBL] [Abstract][Full Text] [Related]
25. Role of nitric oxide and cyclic guanosine 3',5'-monophosphate in the estrogen regulation of cervical epithelial permeability.
Gorodeski GI
Endocrinology; 2000 May; 141(5):1658-66. PubMed ID: 10803574
[TBL] [Abstract][Full Text] [Related]
26. Src kinase mediates phosphatidylinositol 3-kinase/Akt-dependent rapid endothelial nitric-oxide synthase activation by estrogen.
Haynes MP; Li L; Sinha D; Russell KS; Hisamoto K; Baron R; Collinge M; Sessa WC; Bender JR
J Biol Chem; 2003 Jan; 278(4):2118-23. PubMed ID: 12431978
[TBL] [Abstract][Full Text] [Related]
27. Genistein stimulates the osteoblastic differentiation via NO/cGMP in bone marrow culture.
Pan W; Quarles LD; Song LH; Yu YH; Jiao C; Tang HB; Jiang CH; Deng HW; Li YJ; Zhou HH; Xiao ZS
J Cell Biochem; 2005 Feb; 94(2):307-16. PubMed ID: 15526288
[TBL] [Abstract][Full Text] [Related]
28. 17beta-estradiol activates ICI 182,780-sensitive estrogen receptors and cyclic GMP-dependent thioredoxin expression for neuroprotection.
Lee SY; Andoh T; Murphy DL; Chiueh CC
FASEB J; 2003 May; 17(8):947-8. PubMed ID: 12626428
[TBL] [Abstract][Full Text] [Related]
29. NO to breast: when, why and why not?
Pervin S; Chaudhuri G; Singh R
Curr Pharm Des; 2010; 16(4):451-62. PubMed ID: 20236074
[TBL] [Abstract][Full Text] [Related]
30. Click synthesis of estradiol-cyclodextrin conjugates as cell compartment selective estrogens.
Kim HY; Sohn J; Wijewickrama GT; Edirisinghe P; Gherezghiher T; Hemachandra M; Lu PY; Chandrasena RE; Molloy ME; Tonetti DA; Thatcher GR
Bioorg Med Chem; 2010 Jan; 18(2):809-21. PubMed ID: 20031420
[TBL] [Abstract][Full Text] [Related]
31. Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways.
Ghayad SE; Vendrell JA; Ben Larbi S; Dumontet C; Bieche I; Cohen PA
Int J Cancer; 2010 Jan; 126(2):545-62. PubMed ID: 19609946
[TBL] [Abstract][Full Text] [Related]
32. Cytogenetic and cDNA microarray expression analysis of MCF10 human breast cancer progression cell lines.
Marella NV; Malyavantham KS; Wang J; Matsui S; Liang P; Berezney R
Cancer Res; 2009 Jul; 69(14):5946-53. PubMed ID: 19584277
[TBL] [Abstract][Full Text] [Related]
33. ERalpha-negative and triple negative breast cancer: molecular features and potential therapeutic approaches.
Chen JQ; Russo J
Biochim Biophys Acta; 2009 Dec; 1796(2):162-75. PubMed ID: 19527773
[TBL] [Abstract][Full Text] [Related]
34. Estrogen regulation of apoptosis: how can one hormone stimulate and inhibit?
Lewis-Wambi JS; Jordan VC
Breast Cancer Res; 2009; 11(3):206. PubMed ID: 19519952
[TBL] [Abstract][Full Text] [Related]
35. Invited Commentary: Hormone therapy risks and benefits--The Women's Health Initiative findings and the postmenopausal estrogen timing hypothesis.
Banks E; Canfell K
Am J Epidemiol; 2009 Jul; 170(1):24-8. PubMed ID: 19468078
[TBL] [Abstract][Full Text] [Related]
36. Mechanisms of estrogen signaling and gene expression via GPR30.
Prossnitz ER; Maggiolini M
Mol Cell Endocrinol; 2009 Sep; 308(1-2):32-8. PubMed ID: 19464786
[TBL] [Abstract][Full Text] [Related]
37. In vivo effects of a GPR30 antagonist.
Dennis MK; Burai R; Ramesh C; Petrie WK; Alcon SN; Nayak TK; Bologa CG; Leitao A; Brailoiu E; Deliu E; Dun NJ; Sklar LA; Hathaway HJ; Arterburn JB; Oprea TI; Prossnitz ER
Nat Chem Biol; 2009 Jun; 5(6):421-7. PubMed ID: 19430488
[TBL] [Abstract][Full Text] [Related]
38. Estrogen mediation of breast tumor formation involves estrogen receptor-dependent, as well as independent, genotoxic effects.
Santen R; Cavalieri E; Rogan E; Russo J; Guttenplan J; Ingle J; Yue W
Ann N Y Acad Sci; 2009 Feb; 1155():132-40. PubMed ID: 19250200
[TBL] [Abstract][Full Text] [Related]
39. MassMatrix: a database search program for rapid characterization of proteins and peptides from tandem mass spectrometry data.
Xu H; Freitas MA
Proteomics; 2009 Mar; 9(6):1548-55. PubMed ID: 19235167
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
